Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
1
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Background/Aims: The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy. Methods: Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed. Results: Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase. Conclusions: A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.
Abstract
Background/Aims: The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in use correspond to histologic criteria in determining the IT phase and indication for liver biopsy. Methods: Patients in the serological IT phase determined by positive hepatitis B e antigen, hepatitis B virus (HBV) DNA ≥106 IU/mL, and normal or minimally elevated alanine aminotransferase (ALT) ≤60 IU/L, who underwent liver biopsy at three different hospitals were included. The distribution of the histologic IT phase, defined as fibrosis of stage 1 or less and inflammation of grade 1 or less, was compared with that of the serological IT phase. The risk factors for the incidence of liver-related events, such as hepatocellular carcinoma, liver cirrhosis, liver transplantation, and death, were also analyzed. Results: Eighty-two (31.7%) out of 259 clinically suspected IT phase patients belonged to the histologic IT phase. Age over 35, high AST, and low albumin were useful for ruling out the histologic IT phase. Risk factors predicting liver-related events were age and significant fibrosis stage. There was no significant difference in the proportion of histologic IT phase and clinical prognosis between normal ALT and mildly elevated ALT groups. However, even in patients with normal ALT, age was an important factor in predicting the presence of the histologic IT phase. Conclusions: A significant number of patients who belonged to the serological IT phase were not in the histologic IT phase. Patients over 35 years and those with high AST, low albumin, and low HBV DNA levels were more likely to experience poor long-term clinical outcomes. Therefore, additional histologic assessment should be considered.
참고문헌 (31)
- 임선영, "The epidemiology of hepatitis B virus infection in Korea", The Korean Journal of Internal Medicine, 34(5), pp.945~953 (2019), 대한내과학회[DOI]
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
- Hyung Joon Yim, "Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop", Clinical and Molecular Hepatology, 26(4), pp.411~429 (2020), 대한간학회[DOI]
- Nguyen MH, "Histological disease in Asian-Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels", Am J Gastroenterol, 104, pp.2206~2213 (2009)
- Kim GA, "High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
- Chu CM, "Prognosis of immune-tolerant phase chronic hepatitis B", Gut, 67, pp.988~ (2018)
- Neuberger J, "Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology", Gut, 69, pp.1382~1403 (2020)
- Young Chang, "Clinical application of ultrasonography-guided percutaneous liver biopsy and its safety over 18 years", Clinical and Molecular Hepatology, 26(3), pp.318~327 (2020), 대한간학회[DOI]
- Yu E, "Histologic grading and staging of chronic hepatitis: on the basis of standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases", Taehan Kan Hakhoe Chi, 9, pp.42~46 (2003)
- Hartl J, "Transient elastography in autoimmune hepatitis : Timing determines the impact of inflammation and fibrosis", J Hepatol, 65, pp.769~775 (2016)
- Tsochatzis EA, "Liver cirrhosis", Lancet, 383, pp.1749~1761 (2014)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 Practice guidance by the American Association for the study of liver diseases", Hepatology, 68, pp.723~750 (2018)
- Chu CM, "Natural history of chronic hepatitis B virus infection in Taiwan : studies of hepatitis B virus DNA in serum", Hepatology, 5, pp.431~434 (1985)
- Mason WS, "HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant", Gastroenterology, 151, pp.986~998 (2016)
- Henrik Zhang, "Approaches to quantifying hepatitis B virus covalently closed circular DNA", Clinical and Molecular Hepatology, 28(2), pp.135~149 (2022), 대한간학회[DOI]
- Chang MH, "Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period : clinical and liver histologic studies", Hepatology, 8, pp.374~377 (1988)
- Lee HW, "Unresolved issues of immune tolerance in chronic hepatitis B", J Gastroenterol, 55, pp.383~389 (2020)
- Hui CK, "Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase", Hepatology, 46, pp.395~401 (2007)
- Lee HW, "Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals", Sci Rep, 9, pp.2508~ (2019)
- Cha Elliot D. K., "Meeting Patient Expectations or Achieving a Minimum Clinically Important Difference: Predictors of Satisfaction Among Lumbar Fusion Patients", Asian Spine Journal, 16(4), pp.478~485 (2022), 대한척추외과학회[DOI]
- Yamamoto Yoshio, "Psychological Predictors of Satisfaction after Lumbar Surgery for Lumbar Spinal Stenosis", Asian Spine Journal, 16(2), pp.270~278 (2022), 대한척추외과학회[DOI]
- Mi Young Jeon, "Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B", Clinical and Molecular Hepatology, 27(2), pp.295~304 (2021), 대한간학회[DOI]
- Lee HW, "Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B", Eur J Intern Med, 84, pp.68~73 (2021)
- Terry Cheuk-Fung Yip, "Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact", Clinical and Molecular Hepatology, 27(2), pp.273~277 (2021), 대한간학회[DOI]
- Lee HA, "Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase", Aliment Pharmacol Ther, 52, pp.196~204 (2020)
- Wong GL, "Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases", Clin Gastroenterol Hepatol, 6, pp.1027~1035 (2008)
- Yoo JJ, "The influence of histologic inflammation on the improvement of liver stiffness values over 1 and 3 years", J Clin Med, 8, pp.2065~ (2019)
- Martin P, "Immune-tolerant hepatitis B : maybe a misnomer but still hard to treat", Hepatology, 69, pp.2315~2317 (2019)
- Grace Lai-Hung Wong, "Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend", Clinical and Molecular Hepatology, 24(2), pp.108~113 (2018), 대한간학회